BEXIMCO PHARMA.GDR REGS 1 (R2WA) — Tangible Net Worth Ratio
BEXIMCO PHARMA.GDR REGS 1 (R2WA) has a Tangible Net Worth Ratio of 91.2% as of December 2024. This metric is calculated by deducting intangible assets (€4.72 Billion) from net assets (€53.63 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See BEXIMCO PHARMA.GDR REGS 1 current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
BEXIMCO PHARMA.GDR REGS 1 Tangible Net Worth Ratio (2021–2024)
This chart shows how BEXIMCO PHARMA.GDR REGS 1's Tangible Net Worth Ratio has changed across 4 annual periods from 2021 to 2024. As of December 2024, the ratio stands at 91.2%, reflecting net assets of €53.63 Billion with intangible assets of €4.72 Billion EUR. See BEXIMCO PHARMA.GDR REGS 1 liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for BEXIMCO PHARMA.GDR REGS 1 (2021–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for BEXIMCO PHARMA.GDR REGS 1 from 2021 to 2024, covering 4 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see market cap of BEXIMCO PHARMA.GDR REGS 1.
| Year | Tangible NW Ratio | Net Assets (EUR) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 90.9% | €51.90 Billion | €4.72 Billion | €69.34 Billion | ▲ +0.8 pp |
| 2023 | 90.1% | €47.62 Billion | €4.72 Billion | €69.16 Billion | ▲ +0.7 pp |
| 2022 | 89.4% | €44.64 Billion | €4.73 Billion | €66.15 Billion | ▼ -6.9 pp |
| 2021 | 96.3% | €37.36 Billion | €1.38 Billion | €52.25 Billion | — |